What is the most important information I should know about PLUVICTO?
Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased risk for cancer. Drink plenty of water and urinate as often as possible during the first hours after administration.
To minimize radiation exposure to others following administration of PLUVICTO, limit close contact (less than 3 feet) with household contacts for 2 days or with children and pregnant women for 7 days. Refrain from sexual activity for 7 days, and sleep in a separate bedroom from household contacts for 3 days, from children for 7 days, or from pregnant women for 15 days.
PLUVICTO may cause serious side effects, including:
Low level of blood cell counts. Tell your doctor right away if you develop any new or worsening symptoms, including:
Kidney problems. You should stay well-hydrated before and after treatment. Tell your doctor right away if you develop any new or worsening urinary symptoms.
All radiopharmaceuticals, including PLUVICTO, have the potential to cause harm to an unborn baby .
PLUVICTO may cause temporary or permanent infertility.
These are not all of the possible side effects of PLUVICTO. Call your doctor for advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please see full Prescribing Information.
PLUVICTO® is a prescription treatment used to treat adults with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) already treated with:
